FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:812-813 March 18, 1993 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

To the Editor: Juliusson et al. (Oct. 8 issue)¹ describe four patients with chronic lymphocytic leukemia (CLL) who responded well to 2-chlorodeoxyadenosine (one with a complete response and three with partial responses), although their disorder was resistant to a structurally similar compound, fludarabine. We certainly welcome these authors' encouraging observations; however, it cannot be inferred from the results in such a small number of patients that 2-chlorodeoxyadenosine will benefit many patients with fludarabine-resistant CLL. Our experience with 2-chlorodeoxyadenosine in patients with no response to fludarabine has been less satisfactory.

Three patients with CLL that had been heavily pretreated (one patient . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Morris, A. K, Kolesar, J. M, Kuhn, J. G (1997). Review : Purine nucleoside analogs: fludarabine, entostatin and cladribine: Part 3: cladribine. J Oncol Pharm Pract 3: 94-109  
• Fidias, P., Chabner, B. A., Grossbard, M. L. (1996). Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders. The Oncologist 1: 125-139 [Abstract] [Full Text]  
• Juliusson, G., Liliemark, J., Saven, A., Piro, L., O'Brien, S. (1994). 2-Chlorodeoxyadenosine Therapy in Chronic Lymphocytic Leukemia. NEJM 330: 1828-1830 [Full Text]  
• O'Brien, S., Kantarjian, H., Estey, E., Koller, C., Robertson, B., Beran, M., Andreeff, M., Pierce, S., Keating, M. (1994). Lack of Effect of 2-Chlorodeoxyadenosine Therapy in Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine Therapy. NEJM 330: 319-322 [Abstract] [Full Text]